KRAS made a splash at this year’s ASCO after Amgen’s early data for first-to-clinic inhibitor AMG 510 triggered blockbuster chatter. Now one research team has early evidence that the combo could further increase KRAS inhibitors’ therapeutic effects in lung cancer.
